{"id":301299,"date":"2025-06-19T02:38:58","date_gmt":"2025-06-19T02:38:58","guid":{"rendered":"https:\/\/peraltafinancing.com\/uncategorized\/neuroem-therapeutics-closes-initial-rounds-in-5-million-equity-raise-to-commercialize-drug-free-alzheimers-treatment\/"},"modified":"2025-06-19T02:38:58","modified_gmt":"2025-06-19T02:38:58","slug":"neuroem-therapeutics-closes-initial-rounds-in-5-million-equity-raise-to-commercialize-drug-free-alzheimers-treatment","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=301299","title":{"rendered":"NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer\u2019s Treatment"},"content":{"rendered":"


\n<\/p>\n

\n
\n

Jun 13
2025<\/p>\n

NeuroEM Therapeutics Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer\u2019s Treatment<\/h2>\n<\/header>\n

NeuroEM Therapeutics<\/a>, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer\u2019s disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc<\/a>.<\/p>\n

The Series A round supports continued progress toward commercialization of NeuroEM\u2019s Transcranial Electromagnetic Treatment (TEMT-RF)<\/a> to prevent and treat cognitive decline caused by aging or Alzheimer\u2019s and other neurodegenerative diseases.<\/p>\n

\"\"
Chuck Papageorgiou<\/figcaption><\/figure>\n

\u201cBlueLake\u2019s support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer\u2019s dementia and other neurodegenerative diseases,\u201d says Chuck Papageorgiou<\/a>, CEO of NeuroEM Therapeutics. \u201cIt fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer\u2019s disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.\u201d<\/p>\n

The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors.<\/p>\n

He brings more than 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo\u2019s Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson.<\/p>\n

\u201cNeuroEM\u2019s pioneering, non-invasive approach to treating and preventing Alzheimer\u2019s represents exactly the kind of patented, deep tech innovation we champion at BlueLake\u2014transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer\u2019s holds tremendous promise in tackling a disease that has eluded effective solutions for decades,\u201d said Rutledge. \u201cWe\u2019re proud to support the advancement of this groundbreaking technology, and I\u2019m personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.\u201d<\/p>\n

Adds Papageorgiou, \u201cJamie\u2019s background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.\u201d<\/p>\n

NeuroEM Therapeutics, a member of StartUp Health\u2019s Alzheimer\u2019s Moonshot Community<\/a>, is committed to developing, clinically testing, and marketing its multi-patented<\/a> TEMT-RF technologies that target and reduce cognitive decline and restore immune balance in the brain and blood while boosting energy production in brain cells\u2014critical elements for optimal cognitive function. Early studies have demonstrated that, as an Alzheimer\u2019s treatment, TEMT-RF is safe, enhances cognitive function, and may potentially modify the disease itself.<\/p>\n

The company\u2019s first commercial product, a lightweight cap designed for at-home use, is currently under development and has shown extraordinary promise in preclinical and clinical studies<\/a>. Worn for an hour twice daily, the device uses short pulses of energy in specific ultra-high frequencies to deliver a transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline.<\/p>\n

BlueLake Ventures<\/a> invests in applied deep tech for the future of work and health, technology defined by significant barriers to entry, such as strong patent protection or specialized domain expertise. Its team consists of experienced operators who have built and scaled startup companies, held executive positions in multi-national corporations, built partnerships between startups and corporations, and deployed strategic venture capital in technology-driven businesses. By leveraging its expertise, resources, and networks, BlueLake aims to accelerate the growth of deep tech innovations that empower both businesses and consumers.<\/p>\n

<\/p>\n

<\/p>\n